Trials / Completed
CompletedNCT04606134
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
A Single Center, Prospective, Blinded Study to Evaluate the Efficacy and Safety of a Tripeptide/Hexapeptide Topical When Used With Er:YAG Hybrid Laser for the Treatment of Acne Scars
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Hybrid fractional laser | two treatments given one month apart |
| OTHER | Alastin Regenerating Skin Nectar with TriHex Technology | applied twice daily |
| OTHER | Cetaphil face cream | applied twice daily |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2021-06-18
- Completion
- 2021-06-18
- First posted
- 2020-10-28
- Last updated
- 2023-04-13
- Results posted
- 2023-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04606134. Inclusion in this directory is not an endorsement.